Skip to main content

Table 1 Patient characteristics

From: Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community

Clinical  
   Female, n 145 (49%)
   Age, years (SD) 58 (11)
   Median duration of diabetes, months (IQR) 72 (36, 120)
   History of hypertension, n 175 (60%)
   History of dyslipidaemia, n 206 (70%)
   Body mass index, kg/m2 (SD) 31.9 (7.0)
   Systolic blood pressure, mmHg (SD) 134 (18)
   Diastolic blood pressure, mmHg (SD) 81 (11)
   HbA1c, % (SD) 7.3 (1.5)
   Median UACR, mg/mmol (IQR) 1.2 (0.4, 4.0)
   Normal UACR (<2.5 mg/mmol), n 189 (66%)
   Microalbuminuria (UACR 2.5 - 20 mg/mmol), n 72 (25%)
   Macroalbuminuria (UACR ≥20 mg/mmol), n 27 (9%)
Current therapy  
   Oral hypoglycaemic therapy, n 269 (91%)
   Subcutaneous insulin therapy, n 31 (11%)
   Any antihypertensive therapy, n 190 (65%)
   Statin therapy, n 178 (61%)
Echocardiographic characteristics  
   Left ventricular mass, g (SD) 207 (63)
   Left ventricular mass index, g/m2.7 (SD) 51.5 (14.6)
   Left ventricular hypertrophy, n 164 (56%)
Mild, n 52 (18%)
Moderate, n 49 (17%)
Severe, n 63 (21%)
   Regional wall motion abnormality, n 17 (6%)
   Left ventricular systolic dysfunction, n 12 (4%)
   Left ventricular diastolic dysfunction, n 260 (89%)
Abnormal relaxation, n 173 (59%)
Pseudonormal filling, n 87 (30%)
  1. Values represent mean unless stated. Abbreviations: IQR interquartile range, SD standard deviation, UACR urinary albumin:creatinine ratio